Angioplasty Technology Developed at University of Limerick Licensed to Clada Medical

April 16, 2012 – 12:06 pm

Clada Medical

Clada Medical CEO Ray Blowick (left) and University of Limerick researcher Michael Walsh examine prototype angioplasty device.

A technology developed at Ireland’s University of Limerick (UL) that allows for continuous blood flow during angioplasty procedures has been licensed to Clada Medical. Based in Galway, Ireland’s medtech cluster, Clada Medical provides medical device design, research and development, testing and OEM manufacturing services.

During angioplasty, particles of fatty deposits can become dislodged and enter the blood stream, blocking other arteries and triggering strokes or heart attacks, explains lead inventor Dr Michael Walsh in a press release issued by the university. While embolic protection devices are often used to capture and remove the dislodged deposits, the new device combines angioplasty balloon and embolic protection technologies, says Walsh, which enables continuous blood flow.

“In practice, this means the angioplasty balloon can be left in a full inflated state in the artery for a longer period of time than is currently possible,” says Walsh. “This will increase the efficiency of the angioplasty procedure and offers significant potential as a platform for drug-device combinations.”

Clada Medical has particular expertise in balloon mould manufacturing and custom balloon/catheter design. Applying the UL invention to perfusion balloon technology will be very important for the future of the company, says CEO Ray Blowick.

Enterprise Ireland funded the UL research. It was undertaken at the Centre for Applied Biomedical Engineering Research, which is based in the Materials and Surface Science Institute at UL.

Related Posts Plugin for WordPress, Blogger... Norbert Sparrow
Bookmark and Share

Post a Comment